| Original language | English |
|---|---|
| Pages (from-to) | 898-899 |
| Number of pages | 2 |
| Journal | Gastroenterology |
| Volume | 157 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2019 Sep |
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Future Possibility of Mizagliflozin on Functional Constipation and/or Irritable Bowel Syndrome With Constipation. / Fukudo, Shin; Kaku, Kohei.
In: Gastroenterology, Vol. 157, No. 3, 09.2019, p. 898-899.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Future Possibility of Mizagliflozin on Functional Constipation and/or Irritable Bowel Syndrome With Constipation
AU - Fukudo, Shin
AU - Kaku, Kohei
N1 - Funding Information: Conflicts of interest Dr Fukudo reports grants and personal fees from Kissei Pharmaceutical, during the conduct of the study; personal fees from Dainippon Sumitomo Pharma, grants and personal fees from Abott Japan, personal fees from Scampo Pharma, grants from Ono Pharmaceutical, grants and personal fees from Astellas Pharmaceutical, personal fees from Sanwa Chemical Co. Ltd., personal fees from Zeria, personal fees from Glaxo-Smith-Kline, personal fees from Mochida Pharmaceutical, personal fees from Shionogi Pharmaceutical, grants and personal fees from AstraZeneca, grants from Smoking Research Foundation, grants and personal fees from Tsumuta Co, Ltd., personal fees and non-financial support from Miyarisan Pharmaceutical, grants from Kao Co. Ltd., and grants from Zespri Co, Ltd, outside the submitted work. Dr Kaku reports personal fees from Kissei Pharmaceutical, during the conduct of the study; grants and personal fees from Boehringer Ingelheim, grants from Daiichi Sankyo, grants and personal fees from Taisho Toyama Pharmaceutical, grants and personal fees from Mitsubishi Tanabe Pharma, grants and personal fees from Takeda Pharmaceutical, grants and personal fees from Astellas Pharma, personal fees from AstraZeneca, personal fees from Sumitomo Dainippon Pharma, personal fees from Kissei Pharmaceutical, personal fees from Kowa, personal fees from MSD, personal fees from Novartis Pharma, personal fees from Ono Pharmaceutical, personal fees from Sanofi K.K, outside the submitted work. Funding Information: Funding This study was funded by Kissei Pharmaceutical Co., Ltd . Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/9
Y1 - 2019/9
UR - http://www.scopus.com/inward/record.url?scp=85070773152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070773152&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2019.03.075
DO - 10.1053/j.gastro.2019.03.075
M3 - Letter
C2 - 31228444
AN - SCOPUS:85070773152
VL - 157
SP - 898
EP - 899
JO - Gastroenterology
JF - Gastroenterology
SN - 0016-5085
IS - 3
ER -